Search Videos and More
News
Dana-Farber Cancer Institute Faculty Recognized as 2021 ASCO Leaders in Cancer Care
The American Society of Clinical Oncology (ASCO) recognized two Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.
News
Study Uncovers Potent Immunotherapy Approach to Ovarian Cancer Treatment
Immune therapies declare open season on cancer, rousing immune system cells to take up an attack on tumors. But which immune cells join the hunt, which sit it out, and what happens within immune cells that causes them to go on the offensive?
Video
Study of SACI-IO for Triple Negative Metastatic Breast Cancer
Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative metastatic breast cancer.
News
Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy
Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors.
News
Pediatric Fertility Preservation Program
At Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, we value the importance of fertility and reproductive health as it relates to long-term quality of life. As treatment for childhood cancers and blood disorders have improved, more and more survivors are entering their reproductive years and thinking about starting families of their own. The fertility preservation team will work closely with patients’ primary care team to ensure that a fertility consultation takes place as a part of the patient’s comprehensive work-up.
Video
Bladder Cancer Advances
Dana-Farber's Guru Sonpavde, MD discusses two studies with promising results. One study looks at pre-operative therapy, the other study compares an antibody-drug conjugate to chemotherapy in urothelial carcinoma.
Video
Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research
In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.
News
Expert Panel Issues Recommendations for Addressing Cancer Inequities
New recommendations co-developed by Dana-Farber Cancer Institute call for a significant expansion of the National Cancer Institute (NCI) and NCI-designated Comprehensive Cancer Centers to understand the causes of inequities in cancer care and a commitment to building sustained community partnerships to reduce them.
News
In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant
An immune-suppressing drug normally used to treat rheumatoid arthritis could make bone marrow transplant safer, report researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. In a Phase 2 multi-center trial, the drug abatacept (ORENCIA®) reduced rates of severe, acute graft-versus-host disease (GVHD) and boosted rates of survival without acute GVHD or relapse in patients with leukemia and other blood cancers.
News
First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients
The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber Cancer Institute.
Video
Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer
Why test the combination of Trodelvy and pembrolizumab?
News
Study Underscores Need for Multidisciplinary Care for COVID-19 Long-Haulers
Physicians across the country have analyzed the emerging scientific data about the long-term effects of COVID-19, creating an initial knowledge base about the clinical experiences of so-called “long-haulers” – patients with COVID-19 who experience prolonged symptoms and/or the emergence of new ones well after the initial viral infection has resolved. A comprehensive review published today in Nature Medicine offers an initial glimpse of the multi-organ effects of long-term COVID-19 and suggests a framework for the care of COVID-19 long-haulers through dedicated, multidisciplinary clinics.